# The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

> **NCT04694183** · PHASE2 · COMPLETED · sponsor: **Quan Wang** · enrollment: 37 (actual)

## Conditions studied

- Stomach Neoplasms

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** S-1
- **DRUG:** Oxaliplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04694183
- **Lead sponsor:** Quan Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-17
- **Primary completion:** 2023-05-06
- **Final completion:** 2023-05-06
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04694183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04694183, "The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04694183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*